100% Tariff on Patented Pharmaceuticals: What Importers Need to Know About the April 2026 Section 232 Order
100% Tariff on Patented Pharmaceuticals: What Importers Need to Know About the April 2026 Section 232 Order
On April 2, 2026, President Trump signed a proclamation imposing Section 232 tariffs on imports of patented pharmaceuticals and their active pharmaceutical ingredients (APIs). The headline rate is 100% ad valorem — the highest tariff rate applied to any product category under the current administration's trade framework.
The order does not take effect immediately. Large pharmaceutical companies listed in Annex III of the proclamation face a 120-day implementation window, making their effective date July 31, 2026. All other companies subject to the tariff face a 180-day window, with an effective date of September 29, 2026. That gives importers several months to assess their exposure and explore the onshoring incentives built into the proclamation.
What Is Covered
The tariff applies to patented pharmaceutical products and their associated active pharmaceutical ingredients imported into the United States. This is specifically a Section 232 action under the Trade Expansion Act of 1962, based on a Commerce Department finding that foreign dependence on pharmaceutical supply chains constitutes a national security threat.
The scope is broad. Any branded, patent-protected drug product entering the U.S. from a foreign manufacturer is subject to the tariff unless it falls into one of the carveout categories described below.
What Is Exempt
Several important product categories are excluded from the tariff:
Generic pharmaceuticals and biosimilars, along with their associated ingredients, are fully exempt. The proclamation directs a reassessment of generic drug tariff treatment in one year.
Orphan drugs — medications designated for rare diseases under the Orphan Drug Act — are excluded.
Animal health medications are not subject to the tariff.
Certain specialty pharmaceuticals from countries with existing trade agreements, or medications addressing urgent public health needs, may qualify for exemption on a case-by-case basis.
Country-Specific Rates
The proclamation does not apply the 100% rate uniformly. Countries that have negotiated pharmaceutical-specific trade commitments with the United States receive substantially lower rates:
European Union, Japan, South Korea, and Switzerland/Liechtenstein receive a reduced rate of 15% on covered pharmaceutical products under the terms of their respective bilateral agreements.
United Kingdom receives preferential treatment under the U.S.-UK Economic Prosperity Deal, with a rate lower than the default 100%.
All other countries face the full 100% tariff rate unless their manufacturers qualify for reduced rates through onshoring commitments.
Onshoring Incentives
The proclamation includes a structured incentive program designed to move pharmaceutical production to the United States:
Onshoring plan approval: 20% rate. Companies that submit and receive approval for plans to relocate pharmaceutical manufacturing to the U.S. qualify for a reduced 20% tariff rate instead of the default 100%. The Departments of Commerce and Health and Human Services administer this process.
Onshoring plus MFN pricing: 0% rate. Companies that both commit to onshoring production and enter into Most Favored Nation (MFN) pharmaceutical pricing agreements with HHS can qualify for a 0% tariff rate through January 20, 2029. This is the strongest incentive — effectively tariff-free access in exchange for domestic production and pricing concessions.
These incentive provisions reportedly motivated approximately $400 billion in announced pharmaceutical manufacturing investment commitments within days of the proclamation's signing.
How This Affects Landed Costs
Consider a U.S. distributor importing a patented biologic drug from a manufacturer in India (no trade agreement) with a declared customs value of $500,000 per shipment.
Before July 31, 2026:** - Base MFN duty: 0% - Section 301: Not applicable (India is not subject to Section 301) - Section 232: Not applicable to pharmaceuticals - Section 122: 10% = $50,000 - **Total duty: $50,000 — Landed cost: $550,000
After July 31, 2026 (full rate, no onshoring plan):** - Base MFN duty: 0% - Section 232 (pharma): 100% = $500,000 - Section 122: Exempt (Section 232 articles exempt from Section 122) - **Total duty: $500,000 — Landed cost: $1,000,000
After July 31, 2026 (with approved onshoring plan):** - Section 232 (pharma): 20% = $100,000 - **Total duty: $100,000 — Landed cost: $600,000
The difference between the full 100% rate and the 20% onshoring rate is $400,000 on a single $500,000 shipment. For high-volume pharmaceutical importers, the financial pressure to pursue onshoring plans is enormous.
For imports from EU, Japan, South Korea, or Switzerland at the 15% trade-deal rate, that same $500,000 shipment would incur $75,000 in Section 232 duty — a significant cost, but far more manageable than the default.
What Importers Should Do Now
Audit your pharmaceutical supply chain. Identify every patented pharmaceutical product and API you import, the country of origin, and whether your supplier falls under Annex III (120-day) or the general (180-day) timeline.
Determine if trade-deal rates apply. If your products originate in the EU, Japan, South Korea, Switzerland, or the UK, you may qualify for the 15% reduced rate. Confirm with your customs broker that your entries will be properly classified to receive the preferential treatment.
Evaluate onshoring incentives. If you or your manufacturer are considering U.S. production, contact the Department of Commerce to understand the onshoring plan approval process. The difference between 100% and 20% makes this worth serious analysis.
Assess generic alternatives. Since generic pharmaceuticals and biosimilars are exempt, importers with generic equivalents available should evaluate whether switching sourcing makes financial sense under the new tariff structure.
Monitor the Section 122 interaction. Pharmaceutical products subject to the new Section 232 tariff will be exempt from the 10% Section 122 universal tariff (consistent with the February 24, 2026 proclamation excluding Section 232 articles from Section 122). However, generic pharmaceuticals that are NOT subject to Section 232 will continue to face Section 122 duties through July 24, 2026.
Use our Duty & Tariff Calculator to estimate your current landed cost on pharmaceutical and other imports. We will be updating the calculator to include pharmaceutical Section 232 rates when the tariff takes effect on July 31, 2026.
Frequently Asked Questions
Common questions about 100% tariff on patented pharmaceuticals
When do pharmaceutical tariffs take effect?
Large pharmaceutical companies listed in Annex III of the April 2, 2026 proclamation face a July 31, 2026 effective date (120 days). All other companies face a September 29, 2026 effective date (180 days).
Are generic drugs subject to the pharmaceutical tariff?
No. Generic pharmaceuticals, biosimilars, and their associated ingredients are fully exempt from the Section 232 pharmaceutical tariff. The proclamation directs a reassessment of generic drug tariff treatment in one year.
What is the pharmaceutical tariff rate for EU countries?
The EU, Japan, South Korea, and Switzerland/Liechtenstein receive a reduced rate of 15% on covered pharmaceutical products under bilateral trade agreements. All other countries without agreements face the full 100% rate unless they qualify for onshoring incentives.
How can pharmaceutical importers reduce the 100% tariff?
Companies can reduce the rate to 20% by submitting and receiving approval for a plan to relocate manufacturing to the United States. Companies that also enter into MFN pricing agreements with HHS can achieve a 0% rate through January 20, 2029.
Related Tools
Need help applying these concepts to your operation?
Our tools and insights help logistics professionals optimize freight, warehouse, and duty costs.
All free. No signup required.